Sean Moloughney, Editor04.06.21
Deerland Probiotics & Enzymes said its probiotic Bacillus subtilis DE111 has attained a list of published health claims in relationship to its inclusion as a food ingredient under the Food Standards Australia New Zealand (FSANZ) Code.
Companies seeking to make a general level health claim for a food ingredient in Australia and New Zealand must perform a comprehensive and systematic review of evidence of a causal food-health relationship. Deerland conducted this assessment of the probiotic DE111 based on peer-reviewed clinical publications on the strain. As a result, Deerland noted that DE111 is the first Bacillus subtilis probiotic to have food-health supported claims associated with its use in Australia and New Zealand food products.
The claims include “promotes growth of healthy gastrointestinal flora,” “supports growth of beneficial gut bacteria,” “supports and improves digestive health in children and adults,” and “reduces total blood cholesterol or blood LDL cholesterol.”
“DE111 provides unique, specific claims and connects consumers’ growing interest in self-care with products that can deliver on their needs,” said Simon Lord, Deerland’s director of sales for Australia and New Zealand.
Steen Andersen, president of Deerland International, added, “This opens up many opportunities for brands to meet the growing demand for probiotic products in Australia and New Zealand by enhancing their food and beverages with functionality, communicated through science-backed claims.”
In addition to the published notification of claims, DE111 has received a letter of no-objection on its GRAS status from U.S. FDA, non-Novel Food status in both Canada and Australia, as well as approval as a natural health ingredient by Health Canada. Further, DE111 is Star-K Kosher certified and Non-GMO Project verified.
Sean Moloughney has been the Editor of Nutraceuticals World since 2012. He can be reached at SMoloughney@RodmanMedia.com.
Companies seeking to make a general level health claim for a food ingredient in Australia and New Zealand must perform a comprehensive and systematic review of evidence of a causal food-health relationship. Deerland conducted this assessment of the probiotic DE111 based on peer-reviewed clinical publications on the strain. As a result, Deerland noted that DE111 is the first Bacillus subtilis probiotic to have food-health supported claims associated with its use in Australia and New Zealand food products.
The claims include “promotes growth of healthy gastrointestinal flora,” “supports growth of beneficial gut bacteria,” “supports and improves digestive health in children and adults,” and “reduces total blood cholesterol or blood LDL cholesterol.”
“DE111 provides unique, specific claims and connects consumers’ growing interest in self-care with products that can deliver on their needs,” said Simon Lord, Deerland’s director of sales for Australia and New Zealand.
Steen Andersen, president of Deerland International, added, “This opens up many opportunities for brands to meet the growing demand for probiotic products in Australia and New Zealand by enhancing their food and beverages with functionality, communicated through science-backed claims.”
In addition to the published notification of claims, DE111 has received a letter of no-objection on its GRAS status from U.S. FDA, non-Novel Food status in both Canada and Australia, as well as approval as a natural health ingredient by Health Canada. Further, DE111 is Star-K Kosher certified and Non-GMO Project verified.
Sean Moloughney has been the Editor of Nutraceuticals World since 2012. He can be reached at SMoloughney@RodmanMedia.com.
